Device Pulmonary

Aeromini Stent and Delivery System

Payments companies reported to CMS as associated with Aeromini Stent and Delivery System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$22Kassociated payments (2023-2025)
43clinicians with associated payments
1company reporting

By year

2023 $21K
2024 $190
2025 $635

Payments reported as associated with Aeromini Stent and Delivery System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

General Practice $11K
Pulmonary Disease $7,854
Thoracic Surgery (Cardiothoracic Vascular Surgery) $1,872
Critical Care Medicine (Internal Medicine) $750
Hematology & Oncology $214
Surgery $123

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Aeromini Stent and Delivery System

These are the largest totals companies reported as associated with Aeromini Stent and Delivery System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ryan Lewis South Jordan, UT General Practice $11,025.00
Deepankar Sharma Columbus, IN Pulmonary Disease $4,462.00
Mahmoud Moammar Orange, CA Pulmonary Disease $497.01
Kevin Green Jupiter, FL Pulmonary Disease $462.15
Abdulla Majid-Moosa Baton Rouge, LA Critical Care Medicine (Internal Medicine) $461.23
Arwa Al-Bedour Madison, WI Pulmonary Disease $458.17
Nicholas Leblanc Baton Rouge, LA Thoracic Surgery (Cardiothoracic Vascular Surgery) $350.00
Sharad Dass San Jose, CA Critical Care Medicine (Internal Medicine) $288.49
Daniel Cuadrado Tacoma, WA Thoracic Surgery (Cardiothoracic Vascular Surgery) $271.14
Nadeem Ali Hackensack, NJ Pulmonary Disease $254.02

Prescribed Aeromini Stent and Delivery System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.